Detailed View
LGND - Ligand Pharmaceuticals Incorpor
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
5,600,273,920
Adj EBIT (TTM)
141,879,000
Enterprise Value
4,820,868,920
Last Price
279.44
Earnings Yield
2.94%
Return on Capital
12.10%
Capital
1,172,556,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 51,722,000 | 17,368,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 59,666,000 | 13,843,000 |
| 2025-09-30 | 10-Q | 2025 | 115,461,000 | 54,931,000 |
| 2025-06-30 | 10-Q | 2025 | 47,627,000 | 8,444,000 |
| 2025-03-31 | 10-Q | 2025 | 45,333,000 | -36,216,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 42,812,000 | -9,637,000 |
| 2024-09-30 | 10-Q | 2024 | 51,812,000 | 3,143,000 |
| 2024-06-30 | 10-Q | 2024 | 41,531,000 | -19,100,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.